Approval · Notice of Compliance 29731 · 2022
BASAGLAR: Notice of Compliance 29731
Issued December 14, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29731
- Date
- December 14, 2022
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Drug substance manufacturing process changes
- Canadian reference product
- LANTUS
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BASAGLAR | Not yet assigned | — |
Medicinal ingredients
- INSULIN GLARGINE 100 UNIT per ML